Loading...
Development of an amorphous based novel sustained release system for apremilast
Zhang, Qiangnan
Zhang, Qiangnan
Citations
Altmetric:
Genre
Thesis/Dissertation
Date
2020
Advisor
Committee member
Group
Department
Pharmaceutical Sciences
Subject
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.34944/dspace/4710
Abstract
As a small molecule PDE 4 inhibitor, apremilast has drawn much attention for multiple promising indications. However, apremilast is a poorly water-soluble drug and has multiple polymorphic forms. This study aims to develop a sustained-release (SR) amorphous solid dispersion (ASD) system for apremilast. A streamlined material sparing ASD formulation development approach was utilized to identify candidate polymers and optimize drug loading. HPMCAS-M at a 20% drug loading and Copovidone at a 40% drug loading was selected as the lead formulations. A stable single-phase amorphous system of apremilast via spray drying was generated as revealed by XRPD, DMA, micro-dissolution, and accelerated stability testing. The apparent solubility of apremilast was improved up to 9 folds. HPMC was subsequently utilized to compress the produced ASD system into an SR matrix tablet. Release data demonstrated the capacity of HPMC to gradually hydrate and control drug release while suppressing drug recrystallization during the 20-hours period of sustained drug delivery. The designed SR amorphous based matrix system indicates that the delivery system has the ability to enhance apparent solubility, avoid recrystallization or polymorphic transformation by stabilizing its amorphous form, and provide an opportunity to enhance patient compliance by allowing once-daily administration.
Description
Citation
Citation to related work
Has part
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu